LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma
Combining trabectedin with doxorubicin as first-line treatment for metastatic leiomyosarcoma nearly doubled the time to progression compared with doxorubicin alone, and later showed a survival benefit, making it the first combination to beat single-agent doxorubicin in a sarcoma subtype.
Overview
Phase 3 trial of 150 patients with metastatic or unresectable uterine or soft tissue leiomyosarcoma randomised to six cycles of doxorubicin alone or doxorubicin plus trabectedin followed by trabectedin maintenance, with surgery of residual disease allowed.
Median progression-free survival was 12.2 versus 6.2 months (hazard ratio 0.41) and response 36 versus 13 percent; the final analysis showed median overall survival of 33 versus 24 months. Grade 3 to 4 haematological toxicity was much higher with the combination.
- Median progression-free survival 12.2 vs 6.2 months; hazard ratio 0.41.
- Median overall survival 33 vs 24 months at final analysis.
Doxorubicin-trabectedin is a first-line standard for fit patients with metastatic leiomyosarcoma, one of the few histology-specific first-line regimens in sarcoma.
- Substantial haematological toxicity and treatment delays.
- Single-country (French) trial; confirmatory data awaited.
Similar pages
not linked directly; found by shared links- Key paperEORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma
Shares Leiomyosarcoma, Soft tissue sarcoma of the extremity (localised and advanced), The Lancet Oncology, Doxorubicin.
- Key paperSoft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline
Shares Leiomyosarcoma, Retroperitoneal sarcoma, Soft tissue sarcoma of the extremity (localised and advanced).
- Key paperTrabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure
Shares Trabectedin, Leiomyosarcoma.
- Key paperSTRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma
- TrialSTRASS (EORTC 62092)
Shares Leiomyosarcoma, Retroperitoneal sarcoma.
- TermHistotype-tailored therapy
Shares Trabectedin, Soft tissue sarcoma of the extremity (localised and advanced).
- Key paperISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma
Shares Soft tissue sarcoma of the extremity (localised and advanced), The Lancet Oncology.
- TermFNCLCC grade (soft-tissue sarcoma)
Shares Retroperitoneal sarcoma, Soft tissue sarcoma of the extremity (localised and advanced).